查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2127957

心房顫動市場規模、佔有率、成長、全球產業分析、區域趨勢及2026年至2034年預測。

Atrial Fibrillation Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 143 Pages | 商品交期: 2-3個工作天內

價格

心房顫動市場的成長要素

全球心房顫動市場預計到2025年將達到172.4億美元，並在2026年至2034年間從172.4億美元成長至257.5億美元，預測期內（2026-2034年）複合年成長率（CAGR）為4.59%。北美地區引領全球市場，預計2025年將佔38.33%的市場佔有率，主要得益於心血管疾病的高發生率、有利的保險報銷政策、積極的藥物研發以及創新療法的不斷主導。

心房顫動（心房顫動）是最常見的心律不整之一，其特徵是心率不規則且通常過快，會增加中風、心臟衰竭和其他心血管併發症的風險。由於人口老化、肥胖、高血壓、糖尿病和久坐的生活方式，心房顫動的盛行率正在上升。隨著人們對早期診斷和治療的認知不斷提高，醫療專業人員擴大採用先進的抗凝血劑和抗心律不整藥物來改善患者的治療效果。此外，政府的醫療保健政策、不斷擴大的臨床研究以及新療法的開發預計將推動市場在2034年之前保持穩定成長。

市場促進因素

心房顫動市場的主要促進因素之一是心血管疾病負擔日益加重和全球人口老化。根據世界衛生組織（WHO）統計，全球有超過12.8億成年人患有高血壓，高血壓會顯著增加心房顫動的風險。此外，肥胖、糖尿病、吸菸和其他文明病的發生率不斷上升，也導致需要長期管理的心房顫動患者數量持續增加。

對創新藥物研發投入的增加也促進了市場成長。製藥公司正積極研發新一代抗凝血劑和單株抗體，旨在提高療效並最大限度地降低出血風險。監管機構也正在加快產品核准流程，以擴大患者的治療選擇。

市場趨勢

塑造市場格局的關鍵趨勢之一是對新型抗凝血療法和單株抗體日益成長的關注。各公司正大力投資於因子XI/XIa抑制劑和其他創新療法，這些療法與傳統抗凝血劑相比具有更高的安全性。

另一個重要趨勢是直介面服抗凝血劑（DOAC）的日益普及。 DOAC不僅能有效預防卒中，比傳統療法更方便。隨著臨床試驗的增加、策略聯盟的建立以及產品持續創新，預計在預測期內，市場競爭格局將進一步加劇。

市場限制因素

儘管成長前景強勁，但仍有一些挑戰限制市場擴張。由於生產問題、標籤錯誤和品質問題導致的頻繁產品召回，可能會對醫生信心和患者接受度產生負面影響。

此外，心導管電氣燒灼術、左心耳封堵術和其他微創手術等替代療法正在與藥物療法競爭，限制了醫藥市場的整體成長潛力。

市場區隔

按藥物分類

預計到2026年，抗凝血藥物市場將佔全球市場78.92%的佔有率，成為推動全球市場成長的主要動力。這一成長主要得益於各國政府日益重視使用抗凝血藥物預防中風，以及直介面服抗凝血劑（DOAC）獲批上市範圍的擴大。同時，抗心律不整藥物市場也呈現穩定成長態勢，主要得益於持續的臨床研發和新藥的核准。

透過行政途徑

預計到2026年，口服給藥途徑將佔全球市場的84.98%。口服藥物的廣泛普及、患者遵守用藥的提高以及口服抗凝血劑使用率的增加是推動該領域成長的主要因素。靜脈注射途徑在急診治療中仍被使用，但其市場佔有率仍然相對較小。

透過分銷管道

預計到2026年，零售藥局將引領藥品分銷市場，佔48.03%的市場佔有率，這主要得益於其廣泛的覆蓋範圍、便捷的購物體驗以及不斷擴展的藥店網路。同時，隨著患者越來越傾向於選擇宅配服務和藥品折扣，網路藥局也日益受到歡迎。

區域趨勢

北美仍是主要的區域市場，預計2025年市場規模將達66.1億美元，2026年將達到68.5億美元。完善的醫療保健基礎設施、日益​​成長的心房顫動盛行率、活躍的臨床研究以及頻繁的法規核准，都持續支撐著該地區的市場主導地位。美國市場預計到2026年將達到61.4億美元。

預計到 2025 年，歐洲市場規模將達到 44.9 億美元，到 2026 年將達到 47.2 億美元。市場成長的促進因素包括心血管疾病盛行率的上升、老年人口的成長以及對心血管藥物研發的大量投資。

預計亞太地區市場規模將在 2025 年達到 34.6 億美元，並在 2026 年成長至 36.8 億美元。人們意識的提高、醫療保健支出的增加、老年人口的成長以及先進心血管治療的普及，都在持續加速該地區的市場成長。

由於醫療基礎設施的改善、對心房顫動 (AFib) 管理的認知提高以及心血管疾病發病率的上升，拉丁美洲、中東和非洲地區也呈現穩定成長的態勢。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 心律不整的盛行率和發生率：主要地區，2024/2025 年
  • 產業重大發展動態－併購、聯盟與收購
  • 各大公司推出新產品
  • 新冠疫情對心房顫動市場的影響

第5章：2021-2034年全球心房顫動市場分析、洞察與預測

  • 市場分析、洞察與預測：按藥物類別分類
    • 抗凝血物
    • 抗心律不整藥物
  • 市場分析、洞察與預測：按給藥途徑
    • 口服
    • 靜脈
    • 其他
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 網路藥房
    • 零售藥房
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美心房顫動市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲心房顫動市場分析、洞察與預測（2021-2034年）

  • 國家
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區心房顫動市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲心房顫動市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲心房顫動市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Bristol-Myers Squibb Company
    • Sanofi
    • Eisai Co., Ltd.
    • Johnson & Johnson
    • Daiichi Sankyo, Inc.
    • Par Pharmaceutical
    • Bayer AG
    • Pfizer Inc.
Product Code: FBI108921

Growth Factors of atrial fibrillation Market

The global atrial fibrillation market was valued at USD 17.24 billion in 2025 and is projected to grow from USD 17.24 billion in 2026 to USD 25.75 billion by 2034, registering a CAGR of 4.59% during the forecast period (2026-2034). North America dominated the global market with a 38.33% market share in 2025, driven by the high prevalence of cardiovascular diseases, favorable reimbursement policies, strong pharmaceutical research, and continuous introduction of innovative therapies.

Atrial fibrillation (AFib) is one of the most common cardiac arrhythmias characterized by an irregular and often rapid heartbeat, increasing the risk of stroke, heart failure, and other cardiovascular complications. The condition is becoming increasingly prevalent due to aging populations, obesity, hypertension, diabetes, and sedentary lifestyles. As awareness regarding early diagnosis and treatment grows, healthcare providers are increasingly adopting advanced anticoagulants and antiarrhythmic drugs to improve patient outcomes. Furthermore, government healthcare initiatives, expanding clinical research, and the development of novel therapies are expected to support steady market growth through 2034.

Market Drivers

One of the primary drivers of the atrial fibrillation market is the growing burden of cardiovascular diseases and the expanding elderly population worldwide. According to the World Health Organization, hypertension affects more than 1.28 billion adults globally, significantly increasing the risk of atrial fibrillation. In addition, the rising incidence of obesity, diabetes, smoking, and other lifestyle-related disorders continues to increase the patient population requiring long-term AFib management.

The market is also benefiting from increasing investments in innovative drug development. Pharmaceutical companies are actively developing next-generation anticoagulants and monoclonal antibodies designed to improve efficacy while minimizing bleeding risks. Regulatory agencies are further accelerating product approvals to expand treatment options for patients.

Market Trends

A major trend shaping the market is the growing focus on novel anticoagulant therapies and monoclonal antibodies. Companies are investing heavily in Factor XI/XIa inhibitors and other innovative treatments that offer improved safety profiles compared to conventional anticoagulants.

Another significant trend is the increasing adoption of Direct Oral Anticoagulants (DOACs), which provide effective stroke prevention while offering greater convenience than traditional therapies. Rising clinical trials, strategic collaborations, and continuous product innovations are expected to strengthen the competitive landscape during the forecast period.

Market Restraints

Despite favorable growth prospects, several challenges continue to restrain market expansion. Frequent product recalls due to manufacturing issues, labeling errors, and quality concerns may negatively affect physician confidence and patient adoption.

Additionally, alternative treatment options such as catheter ablation, left atrial appendage closure procedures, and other minimally invasive interventions provide competition for pharmacological therapies, limiting the overall growth potential of the drug market.

Market Segmentation

By Drug Class

The anticoagulants segment is expected to dominate the global market with a 78.92% share in 2026. Increasing government recommendations supporting anticoagulant use for stroke prevention, coupled with growing approvals of Direct Oral Anticoagulants (DOACs), continue to strengthen this segment. Meanwhile, the antiarrhythmic drugs segment is also witnessing steady growth owing to ongoing clinical development and new drug approvals.

By Route of Administration

The oral segment is projected to account for 84.98% of the global market in 2026. The widespread availability of oral medications, improved patient compliance, and increasing adoption of oral anticoagulants are driving segment growth. The intravenous segment continues to serve emergency treatment settings but represents a comparatively smaller share.

By Distribution Channel

Retail pharmacies are expected to lead the distribution landscape with a 48.03% market share in 2026 due to their broad accessibility, consumer convenience, and expanding pharmacy networks. Online pharmacies are also gaining popularity as patients increasingly prefer home delivery services and discounted medication pricing.

Regional Insights

North America remained the leading regional market, generating USD 6.61 billion in 2025, and is expected to reach USD 6.85 billion in 2026. Strong healthcare infrastructure, increasing prevalence of atrial fibrillation, active clinical research, and frequent regulatory approvals continue to support regional dominance. The U.S. market is projected to reach USD 6.14 billion in 2026.

Europe accounted for USD 4.49 billion in 2025 and is projected to reach USD 4.72 billion in 2026. Market growth is supported by increasing cardiovascular disease prevalence, expanding geriatric population, and significant investments in cardiovascular drug development.

Asia Pacific generated USD 3.46 billion in 2025 and is expected to grow to USD 3.68 billion in 2026. Rising awareness, growing healthcare expenditure, increasing elderly populations, and expanding access to advanced cardiovascular treatments continue to accelerate regional market growth.

Latin America and the Middle East & Africa are also witnessing steady expansion due to improving healthcare infrastructure, greater awareness regarding AFib management, and rising cardiovascular disease incidence.

Competitive Landscape

The atrial fibrillation market is moderately consolidated, with major pharmaceutical companies focusing on expanding product portfolios through clinical research, strategic collaborations, and geographic expansion. Leading market participants include Bristol-Myers Squibb Company, Bayer AG, Daiichi Sankyo, Sanofi, Johnson & Johnson, Pfizer Inc., Eisai Co., Ltd., and Par Pharmaceutical. Continuous investment in innovative anticoagulants and next-generation cardiovascular therapies is expected to intensify competition throughout the forecast period.

Recent Industry Developments

  • In November 2023, Bayer AG expanded its Phase III clinical trials for asundexian, targeting stroke prevention in atrial fibrillation patients.
  • In March 2023, Bristol Myers Squibb and Janssen Pharmaceuticals initiated the Phase III Librexia trial to evaluate Milvexian for stroke prevention.
  • In July 2022, InCarda Therapeutics enrolled the first patient in its pivotal Restore-1 Phase III clinical trial for InRhythm.
  • In June 2022, Apotex launched the generic anticoagulant APO-Apixaban in Canada.
  • In June 2019, TOA EIYO Ltd. and Astellas Pharma introduced Bisono Tape 2 mg, a B1-blocker transdermal patch for atrial fibrillation treatment in Japan.

Conclusion

The global atrial fibrillation market is expected to witness steady growth through 2034, supported by the increasing prevalence of cardiovascular diseases, expanding geriatric population, and rising demand for advanced anticoagulant therapies. Continuous innovation in drug development, favorable regulatory support, growing awareness regarding stroke prevention, and expanding healthcare access are expected to create significant opportunities for pharmaceutical companies. Despite challenges such as product recalls and competition from interventional treatment options, the market is well-positioned for sustained long-term growth as healthcare systems increasingly prioritize effective atrial fibrillation management.

Segmentation By Drug Class

  • Anticoagulants
  • Antiarrhythmic Drugs

By Route of Administration

  • Oral
  • Intravenous
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

By Region

  • North America (By Drug Class, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • India
    • Japan
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence/Incidence of Arrhythmia, Key Region, 2024/2025
  • 4.2. Key Industry Developments - Mergers, Partnerships, Acquisitions
  • 4.3. New Product Launches by Key Players
  • 4.4. Impact of COVID-19 on Atrial Fibrillation Market

5. Global Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Anticoagulants
    • 5.1.2. Anti-arrhythmic Drugs
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Intravenous
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Online Pharmacies
    • 5.3.3. Retail Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Anticoagulants
    • 6.1.2. Anti-arrhythmic Drugs
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Intravenous
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Online Pharmacies
    • 6.3.3. Retail Pharmacies
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
      • 6.4.1.1. By Drug Class
    • 6.4.2. Canada
      • 6.4.2.1. By Drug Class

7. Europe Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Anticoagulants
    • 7.1.2. Anti-arrhythmic Drugs
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Intravenous
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Online Pharmacies
    • 7.3.3. Retail Pharmacies
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.4.1. Germany
      • 7.4.1.1. By Drug Class
    • 7.4.2. U.K.
      • 7.4.2.1. By Drug Class
    • 7.4.3. France
      • 7.4.3.1. By Drug Class
    • 7.4.4. Spain
      • 7.4.4.1. By Drug Class
    • 7.4.5. Italy
      • 7.4.5.1. By Drug Class
    • 7.4.6. Scandinavia
      • 7.4.6.1. By Drug Class
    • 7.4.7. Rest of Europe
      • 7.4.7.1. By Drug Class

8. Asia Pacific Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Anticoagulants
    • 8.1.2. Anti-arrhythmic Drugs
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Intravenous
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Online Pharmacies
    • 8.3.3. Retail Pharmacies
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.4.1. Japan
      • 8.4.1.1. By Drug Class
    • 8.4.2. China
      • 8.4.2.1. By Drug Class
    • 8.4.3. India
      • 8.4.3.1. By Drug Class
    • 8.4.4. Australia
      • 8.4.4.1. By Drug Class
    • 8.4.5. Southeast Asia
      • 8.4.5.1. By Drug Class
    • 8.4.6. Rest of Asia Pacific
      • 8.4.6.1. By Drug Class

9. Latin America Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Anticoagulants
    • 9.1.2. Anti-arrhythmic Drugs
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Intravenous
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Online Pharmacies
    • 9.3.3. Retail Pharmacies
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.4.1. Brazil
      • 9.4.1.1. By Drug Class
    • 9.4.2. Mexico
      • 9.4.2.1. By Drug Class
    • 9.4.3. Rest of Latin America
      • 9.4.3.1. By Drug Class

10. Middle East & Africa Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Anticoagulants
    • 10.1.2. Anti-arrhythmic Drugs
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Intravenous
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Online Pharmacies
    • 10.3.3. Retail Pharmacies
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.4.1. GCC
      • 10.4.1.1. By Drug Class
    • 10.4.2. South Africa
      • 10.4.2.1. By Drug Class
    • 10.4.3. Rest of Middle East & Africa
      • 10.4.3.1. By Drug Class

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Bristol-Myers Squibb Company
      • 11.2.1.1. Overview
      • 11.2.1.2. Product
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. financials (Based on Availability)
    • 11.2.2. Sanofi
      • 11.2.2.1. Overview
      • 11.2.2.2. Product
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. financials (Based on Availability)
    • 11.2.3. Eisai Co., Ltd.
      • 11.2.3.1. Overview
      • 11.2.3.2. Product
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. financials (Based on Availability)
    • 11.2.4. Johnson & Johnson
      • 11.2.4.1. Overview
      • 11.2.4.2. Product
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. financials (Based on Availability)
    • 11.2.5. Daiichi Sankyo, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Product
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. financials (Based on Availability)
    • 11.2.6. Par Pharmaceutical
      • 11.2.6.1. Overview
      • 11.2.6.2. Product
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. financials (Based on Availability)
    • 11.2.7. Bayer AG
      • 11.2.7.1. Overview
      • 11.2.7.2. Product
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. financials (Based on Availability)
    • 11.2.8. Pfizer Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Product
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. financials (Based on Availability)

List of Tables

  • Table 1: Global Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Atrial Fibrillation Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Atrial Fibrillation Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Atrial Fibrillation Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 6: North America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 7: North America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Atrial Fibrillation Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: U.S. Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 10: Canada Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 11: Europe Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 12: Europe Atrial Fibrillation Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 13: Europe Atrial Fibrillation Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 14: Europe Atrial Fibrillation Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 15: Germany Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 16: U.K. Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 17: France Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 18: Italy Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 19: Spain Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 20: Scandinavia Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 21: Rest of Europe Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 22: Asia Pacific Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 23: Asia Pacific Atrial Fibrillation Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 24: Asia Pacific Atrial Fibrillation Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Asia Pacific Atrial Fibrillation Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Japan Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 27: India Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 28: China Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 29: Australia Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 30: Southeast Asia Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 31: Rest of Asia Pacific Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 32: Latin America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 33: Latin America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 34: Latin America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 35: Latin America Atrial Fibrillation Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 36: Brazil Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 37: Mexico Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 38: Rest of Latin America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 39: Middle East & Africa Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 40: Middle East & Africa Atrial Fibrillation Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 41: Middle East & Africa Atrial Fibrillation Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 42: Middle East & Africa Atrial Fibrillation Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 43: GCC Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 44: South Africa Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 45: Rest of Middle East & Africa Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034

List of Figures

  • Figure 1: Global Atrial Fibrillation Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Atrial Fibrillation Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Atrial Fibrillation Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Atrial Fibrillation Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Atrial Fibrillation Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 7: North America Atrial Fibrillation Market Value Share (%), by Drug Class, 2025
  • Figure 8: North America Atrial Fibrillation Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 9: North America Atrial Fibrillation Market Value Share (%), by Route of Administration, 2025
  • Figure 10: North America Atrial Fibrillation Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Atrial Fibrillation Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Atrial Fibrillation Market Value Share (%), By Country, 2025
  • Figure 14: Europe Atrial Fibrillation Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 15: Europe Atrial Fibrillation Market Value Share (%), by Drug Class, 2025
  • Figure 16: Europe Atrial Fibrillation Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 17: Europe Atrial Fibrillation Market Value Share (%), by Route of Administration, 2025
  • Figure 18: Europe Atrial Fibrillation Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Atrial Fibrillation Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Atrial Fibrillation Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Atrial Fibrillation Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 23: Asia Pacific Atrial Fibrillation Market Value Share (%), by Drug Class y, 2025
  • Figure 24: Asia Pacific Atrial Fibrillation Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 25: Asia Pacific Atrial Fibrillation Market Value Share (%), by Route of Administration, 2025
  • Figure 26: Asia Pacific Atrial Fibrillation Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Atrial Fibrillation Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Atrial Fibrillation Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Atrial Fibrillation Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 31: Latin America Atrial Fibrillation Market Value Share (%), by Drug Class, 2025
  • Figure 32: Latin America Atrial Fibrillation Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 33: Latin America Atrial Fibrillation Market Value Share (%), by Route of Administration, 2025
  • Figure 34: Latin America Atrial Fibrillation Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Atrial Fibrillation Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Atrial Fibrillation Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Atrial Fibrillation Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 39: Middle East & Africa Atrial Fibrillation Market Value Share (%), by Drug Class, 2025
  • Figure 40: Middle East & Africa Atrial Fibrillation Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 41: Middle East & Africa Atrial Fibrillation Market Value Share (%), by Route of Administration, 2025
  • Figure 42: Middle East & Africa Atrial Fibrillation Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Atrial Fibrillation Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Atrial Fibrillation Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Atrial Fibrillation Market Share (%), By Company, 2025